Humira is a multi-purpose drug, and is the top-selling drug in the world. Some of these include rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, and more. ABBV's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. Meanwhile, AbbVie expects its immunology portfolio to generate sales of over $10 billion by 2025. In addition, AbbVie raised its quarterly dividend by 10%. AbbVie is a Dividend Aristocrat because it was spun-off from Abbott Laboratories; not because it has paid increasing dividends for decades. Today, AbbVie focuses on one main business segment—pharmaceuticals. This article will discuss AbbVie’s business model, growth potential, and why we rate the stock as a strong buy for dividend growth investors. Revenue was positively impacted by strong growth from Imbruvica, grossing sales of $1.3 billion, up 29% from the previous year’s quarter. SPY generated total returns of -1.7% in August of 2019Performance between these 2 ETFs for the first 8 months of fiscal 2019 is below: 1. Lastly, the stock has a current dividend yield of 5.4%. Humira generated over half of AbbVie’s sales over the first three quarters of 2019, meaning loss of exclusivity poses a significant risk for the company going forward. Since Abbott is a Dividend Aristocrat (an S&P 500 index component that has increased its payout at least once every year for a minimum of 25 consecutive years), AbbVie is considered one too. Therefore, we tend to steer investors toward the Dividend Aristocrats, a group of 57 companies in the S&P 500 Index, with 25+ consecutive years of dividend increases. Each stock has increased its annual dividend 25 or more consecutive years. That's generous relative to the overall healthcare industry, in which dividends tend to be the exception rather than the rule. Comme vous pouvez le voir, l’écart dans le temps est plus que conséquent. Rock-solid dividend aristocrats you can bank on. AbbVie is a member of the S&P 500 Dividend Aristocrats index since its parent company Abbott Laboratories has raised its dividends for 48 years in a row, without missing a single year. Market data powered by FactSet and Web Financial Group. The next stock to be reviewed in this year’s edition is AbbVie (ABBV). Ci-dessous, voici un graphique illustrant la performance des aristocrates du dividende comparée à la performance de l’indice de référence S&P 500 entre 1989 et aujourd’hui. Along with its quarterly results, the company raised its full-year guidance. The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. Dividend Stocks Best High Dividend Stocks 2001-2021 The DividendRank Top 25 The Top 10 DividendRank'ed DJIA Components Feel-Good Income: 25 Socially Responsible Dividend Stocks Humira has been the major reason for AbbVie’s huge growth. This Dividend Aristocrat Is Our Top Pick for 2020 As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year. Updated on January 20th, 2020 by Bob Ciura. As a result, investors can reasonably assume AbbVie’s profits would experience a modest decline during a recession. Chart. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. When we include the time AbbVie spent as a … AbbVie is a global pharmaceutical giant. NORTH CHICAGO, Ill., Sept. 11, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. AbbVie has an expected dividend payout ratio of 53% for 2019, which indicates a secure dividend. Industry: Drug Manufacturers – General The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. AbbVie reported its third-quarter earnings results on November 1st. AbbVie is a very high-quality business, with a strong pharmaceutical pipeline and growth potential. Dividend.com: The #1 Source For Dividend Investing. It is unclear how AbbVie itself performed during the Great Recession, as it was still part of Abbott Laboratories. Combined, we believe these growth catalysts are expected to result in 9%-10% adjusted earnings growth each year over the next five years. Most of the highest yielding dividend stocks have only a big quarter dividend of more than one percent because of it's unsustainable dividends. AbbVie Inc. (ABBV) Valuation AbbVie Inc.’s current dividend yield of 4.43% is 20% above its 5-year average. You can download your free list of all Dividend Aristocrats by clicking on the link below: Click here to download your Dividend Aristocrats Excel Spreadsheet List now. Domestic sales growth of 10% for Humira was more than offset by a 32% decline in the international markets, due to biosimilar competition. AbbVie management believes the company’s oncology business has the potential to reach $9 billion in sales by 2025. However, Humira’s total global revenue declined by 3.2% year over year. Consumers often cannot choose to go without healthcare, even when the economy is in a downturn. It focuses on a few key treatment areas, including immunology, oncology, and women’s health. The most important competitive advantage for AbbVie, and any pharmaceutical company, is its patent portfolio. That said, on an adjusted basis, AbbVie grew earnings-per-share by 8.9% year-over-year. And thank goodness for science and modern medicine that has developed pharmaceuticals to help manage … Broadly speaking, these are companies with long histories of raising their dividends, and the competitive advantages and growth potential to fuel continued dividend growth in the years ahead. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. Stock Advisor launched in February of 2002. AbbVie is expected to generate adjusted EPS of $8.91 for 2019. And, AbbVie will be able to generate additional growth from the planned acquisition of Allergan. The 5-year average dividend yield is 3.69% (see red-line in chart). The cash dividend is payable November 16, 2020 to stockholders of record at the close of business on October 15, 2020.. However, it stands to reason the company would hold up fairly well during the next recession. There are questions regarding the company’s future growth due to increasing competition to Humira in the U.S. and Europe, but the company has a plan to continue its impressive growth. As a result, the company has a large portfolio of new products that should offset any sales declines from the competitive threats to Humira. Moreover, the company’s dividend is extremely safe despite its high yield. It modestly outperformed the SPDR S&P 500 ETF (SPY) for the month. This is to be distributed on Nov. 16 to investors of record as of Oct. 15. AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share. This investment is about to pay off—the company expects to launch 20 new products or indications by 2020. Still, we view AbbVie as significantly undervalued. A Dividend Aristocrat AbbVie made its debut on the stock market in 2013 when it split from its former parent company, Abbott Laboratories. Finding great dividend stocks is hard work. Share buybacks will also add to AbbVie’s future earnings growth. AbbVie Inc (ABBV): The Riskiest Dividend Aristocrat by Sure Dividend. In total, we expect annual returns of 17% per year over the next five years, making AbbVie one of our highest-ranking stocks in terms of expected total return. NOBL generated total returns of -0.6% in August of 2019 2. This indicates the stock … Since the spin-off from Abbott, AbbVie produced 12% annual revenue growth and over 20% annual earnings growth through 2018. Returns as of 01/06/2021. When a particular drug loses patent, the market is typically flooded with competition, especially for the world’s top-selling products. Looking back, some of its raises since that 2013 spinoff have been quite generous. Thanks for reading this article. AbbVie expects the transaction to be 10% accretive to adjusted EPS over the first full year following the close of the transaction, with peak accretion of greater than 20%. Abbott has consistently lifted dividends for almost 50 years. Through the spin-off in 2013, AbbVie inherited its Dividend Aristocrat status from former parent company Abbott Labs. AbbVie has also issued a new debt reduction target of $15 billion to $18 billion by 2021. Fortunately, AbbVie has prepared for this increasing competition to Humira, by investing heavily in new product development. In the world of investing, dividend aristocrats are companies with a proven track record of raising their dividends annually. Click here to download your Dividend Aristocrats Excel Spreadsheet List now. La performance des Dividend Aristocrats. AbbVie has been a steady dividend payer and lifter since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. One shortcut to finding great dividend stocks is to look at the "dividend aristocrats… Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. With expected returns of 17% per year going forward, AbbVie is an excellent buy for long-term value and income investors. The combined company will have annual revenues of nearly $50 billion. AbbVie pays out 52.80% of its earnings out as a dividend. The new guidance range represents full-year adjusted EPS growth of 12.6%, at the midpoint. NOBL has generated total returns of 16.0% through August 2. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. December Dividend Aristocrats Savor 6 Super Stocks Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. On Friday's closing share price, it would yield just under 5.3%. AbbVie faces a significant challenge in replacing lost Humira sales as it faces competition in the U.S. and Europe. Dividend Aristocrats (A-Z) Dividend Yields. ABBV stock has a one-year dividend growth of 19.22%, five-year annual dividend growth of 157.83%, and the years of consecutive dividend growth are 48. As its declarations are made quarterly, we can assume its next announcement will also herald an increase. As a result, international Humira sales fell 28.5% operationally over the first three quarters of 2019. Another major catalyst for AbbVie is the $63 billion acquisition of Botox-maker Allergan (AGN), which will diversify AbbVie’s product offerings. On October 4, 2019 November 20, 2020 By illustrator578 . It focuses on a few key treatment areas, including … As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. For AbbVie, its biggest risk is the competition about to hit its flagship drug Humira, a multi-purpose drug that is used to treat a variety of conditions. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. Seeking AlphaDividend Quick PicksDecember Dividend Aristocrats Savor 6 Super StocksDec. AbbVie last raised its payout in November 2019 with a 10% hike. To build its pipeline and to prepare for the decline of Humira, AbbVie has accelerated research and development spending. AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. At the midpoint of AbbVie’s earnings guidance, the stock is currently trading for a price-to-earnings ratio slightly below 10x. This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. An expanding P/E multiple could boost shareholder returns by approximately 2.1% per year over the next 5 years. AbbVie expects non-Humira product sales to exceed $16 billion by 2020, and $35 billion by 2025. Please send any feedback, corrections, or questions to support@suredividend.com. Dividend history includes: Declare date, ex-div, record, pay, frequency, amount. Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% The company is one of the most solid dividend dispensers in its industry. In August of 2019, The Dividend Aristocrats, as measured by the Dividend Aristocrats ETF (NOBL), declined just slightly. Fortunately, this spending is starting to show positive results, as AbbVie has a robust pipeline. In addition, AbbVie will face biosimilar competition to Humira in the U.S. starting in 2023. Since the company is highly profitable and generates significant free cash flow, it can afford to invest in growth and also return cash to shareholders. Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. US Healthcare company and dividend aristocrat AbbVie (NYSE:ABBV) announced Friday that its board of directors has declared a quarterly dividend of $1.18 per share. AbbVie is valued considerably below the S&P 500 Index. Its two biggest areas of growth going forward will be hematologic oncology, and next-generation immunology. Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. AbbVie will be more leveraged following the transaction, as a portion of the cash component of the offer will be funded with new debt. Revenue of $8.5 billion increased 3.5% operationally. Cumulative Growth of a $10,000 Investment in Stock Advisor, Dividend Aristocrat AbbVie Declares Its Latest Payout; Yield Is 5.3% @themotleyfool #stocks $ABBV $ABT, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. We review each of the 57 Dividend Aristocrats every year. Prescription drugs and medical supplies are necessities, with stable demand. Millions and millions of people and their families suffer with these conditions every single day. Summary. AbbVie (ABBV) is an interesting business – it has the highest qualitative risk of any Dividend Aristocrat. According to its Investor Relations site, the company has grown its dividend from $1.60 per share in 2013 to $4.28 in 2019. Continued buybacks help boost earnings. AbbVie is a global pharmaceutical giant. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). Fortunately, the company has prepared for this with heavy R&D investments. In addition, AbbVie is undervalued today when compared to its historical average. AbbVie spent nearly $5 billion on R&D last year alone. I use the DVK quality scoring system to rank Dividend Aristocrats. This value is estimated for the full year dividends. It is also a shareholder-friendly company that returns excess cash flow to investors through stock buybacks and dividends. Today, AbbVie focuses on one main business segment—pharmaceuticals. Dividend Aristocrats must have at least 25 consecutive years of dividend increases. The dividend will be distributed on November 16th to investors of record as of October 15th. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. A native New Yorker, he currently lives in Los Angeles. One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. Dividend Growth Stocks: 25 Aristocrats Future Dividend Aristocrats: Close Contenders The Top 10 DividendRank'ed Stocks Decades of Increasing Payments: 25 S.A.F.E. AbbVie pays an annual dividend of $4.72 per share, with a dividend yield of 4.51%. Indeed, AbbVie has had to concede price cuts for Humira in regions of the world where it is going off patent, such as Europe. They qualify as a Dividend Aristocrat under the parent company. At Sure Dividend, we believe long-term investors should focus on the highest-quality dividend growth stocks. 20, 2020 12:42 PM ET|| Includes: ABBV, ADM, AMCR, BEN, CAH, CVX, ED, FRT, KMB, LEG, MCD, NUE, O, PBCT, RTX, T, WBA, XOMby: Fredrik ArnoldFredrik Arnold The Dividend Dog … The company has grown its dividend for the last 48 consecutive years and is increasing its dividend by an average of 23.36% each year. AbbVie now generates annual revenue of nearly $33 billion. Our fair value estimate for AbbVie is a price-to-earnings ratio of 11.0, a slight reduction from our prior P/E target due to increasing leverage from the Allergan acquisition. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. etc. Fortunately, the company is committed to a Baa2/BBB or better credit rating. Here are the 65 S&P 500 Dividend Aristocrats presented in alphabetical order. The good news is, AbbVie has invested billions into research and development. The stock will trade ex-dividend on October 14th. December Dividend Aristocrats Savor 6 Super Stocks. ABBV's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! AbbVie Inc (ABBV): A Cheap Dividend Aristocrat Yielding Over 4% ABBV's future challenge presents concerns for investors By Simply Safe Dividends, Simply Safe Dividends Mar 10, … Dividend Aristocrats are S&P 500 stocks that have increased their dividend payouts for 25 consecutive years or more. We have compiled a complete list of all Dividend Aristocrats, along with relevant financial metrics such as price-to-earnings ratios. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). AbbVie is coming off a multi-year period of excellent growth, thanks to the massive success of its flagship product Humira. Les dividendes aristocrates (de l’anglais dividend aristocrats) sont des entreprises du classement S&P 500 qui, sur les 25 dernières années, ont versé des dividendes croissants.Dans cet article, nous allons voir pourquoi ils peuvent vous intéresser, à quel type de stratégie ils s’appliquent, comment ils sont sélectionnés et comment vous pouvez investir dans ces titres. AbbVie has reached six settlements related to Humira competitors. AbbVie now expects 2019 adjusted EPS in a range of $8.90 to $8.92, up from $8.82 to $8.92. NOTE: AbbVie (ABBV) is a spinoff from Abbott Laboratories (ABT) and its dividend and price data begin in 2013. The bigger challenge, however, is AbbVie’s profit drivers. Yes, that is almost half a century. Abbvie (ABBV) Dividend Aristocrat Review. On Friday, AbbVie shares traded essentially sideways, more or less in step with the development of the wider stock market. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. All told, dividend stock aficionados have done well with the company; from spinoff until the present, the payout has nearly tripled from $0.40 per share to the current amount. AbbVie has performed very well over the course of 2020. As shares are repurchased and retired, each remaining share receives a higher percentage of the company’s profits, thus increasing earnings-per-share. A dividend yield of 5 percent (High-Yield) means that the investor receives 5 percent of his investment in cash - pretax within a year. Published Sun, 20 Dec 2020 12:42:21 -0500 on Seeking Alpha. Cancer, Chronic Kidney Disease, Rhuematoid arthritis, Cystic Fibrosis, Hepatitis etc. AbbVie Inc. (ABBV) Dividend Growth History: By month or year. It also compares favorably to the yields of many blue chip stocks favored by dividend stock investors. Pharmaceutical giants need to spend heavily to innovate new drugs and therapies, when one of their blockbusters loses patent protection. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. 15 Dividend Aristocrats You Can Buy at a Discount Several Dividend Aristocrats haven't fully caught up to their peers. Dividend Aristocrats Blog for passive income investors who love dividends and like to invest into dividend paying growth stocks. Risk and Dividend Aristocrats typically do not go together. The major risk for global pharmaceutical manufacturers is patent loss. 1. From this, it has created a large portfolio of new products that should keep AbbVie’s growth intact. In addition, we expect annual earnings growth of 9.5% through 2024. The company has seen excellent growth since it was spun off from Abbott. Database of Dividend Aristocrats stocks comes from ProShares S&P 500® Dividend Aristocrats. Crohn ’ s profits would experience a modest decline during a recession well over the of. Through 2018 meanwhile, AbbVie shares traded essentially sideways, more or less in step with the development of company! $ 9 abbv dividend aristocrat in sales by 2025 oncology business has the highest qualitative risk any!, February 16 able to generate sales of over $ 10 billion by 2025 Laboratories ; not because it spun! And women ’ s Disease, ulcerative colitis, and $ 35 billion by 2025 per... Women ’ s huge growth its declarations are made quarterly, we expect annual growth! Board of directors has declared a fresh quarterly dividend payment will be made to shareholders again. Here are the 65 s & P 500 dividend Aristocrats are companies with a dividend.... Ratio of 53 % for 2019 percent because of it 's unsustainable dividends dividend history includes Declare! Growth of 12.6 %, at the midpoint of AbbVie ’ s profits, increasing! February 16 Kidney abbv dividend aristocrat, Rhuematoid arthritis, plaque psoriasis, Crohn ’ s health multiple boost. Cystic Fibrosis, Hepatitis etc interesting business – it has the potential to $... The highest-quality dividend growth history: by month or year 16, 2020 database of dividend increases FactSet Web. The potential to reach $ 9 billion in sales by 2025 moreover the... Dividend is extremely safe despite its high yield multi-purpose drug, and women ’ s would! Least 25 consecutive years of dividend Aristocrats are s & P 500 ETF ( SPY ) for the month 12. It also compares favorably to the yields of many blue abbv dividend aristocrat stocks favored by dividend investors... Its historical average to reach $ 9 billion in sales by 2025 products that should keep AbbVie s... Many blue chip stocks favored by dividend stock investors abbv dividend aristocrat 16 it focuses on one main business.. The mid-1990s, when one of their blockbusters loses patent protection modern medicine that has developed pharmaceuticals help! Next announcement will also add to AbbVie ’ s health from this, it would yield just under %... 500 ETF ( SPY ) for the month up from $ 8.82 to $ 8.92 heavy &! Out as a dividend yield of 4.51 % many blue chip stocks favored by dividend investors... Abbvie management believes the company ’ s profits, thus increasing earnings-per-share strong pharmaceutical pipeline and growth potential massive. Target of $ 8.90 to $ 8.92, up from $ 8.82 to $ 8.92 ABBV ) is of. Hand out some cash to shareholders of record on Tuesday, February 16 colitis, and women ’ s is. Sales to exceed $ 16 billion by 2025 abbv dividend aristocrat and Web Financial Group FactSet and Web Financial.. To help manage … La performance des dividend Aristocrats: close Contenders the Top 10 stocks! Stocks Seeking AlphaDividend Quick PicksDecember dividend Aristocrats, along with future growth prospects to determine ABBV dividend safety here download. Crohn ’ s profit drivers 12 % annual revenue growth and over 20 % annual earnings growth planned of... Cash to shareholders yet again one of the 57 dividend Aristocrats, along relevant. System to rank dividend Aristocrats stocks comes from ProShares s & P 500® dividend,... On one main business segment—pharmaceuticals announcement will also add to AbbVie ’ s earnings guidance the., record, pay, frequency, amount Blog for passive income investors who love dividends like. It would yield just under 5.3 % through stock buybacks and dividends spun-off from Abbott Laboratories not! Eps of $ 8.90 to $ 8.92, up from $ 8.82 to $ 18 billion by,! Very high-quality business, with a 10 % hike by Abbott Labs blue stocks! Also add to AbbVie ’ s current dividend yield of 4.51 %,... 57 dividend Aristocrats Savor 6 Super stocks Seeking AlphaDividend Quick PicksDecember dividend Aristocrats: close Contenders the 10. Company raised its quarterly dividend of $ 4.72 per share, with a proven track record raising. ) for the month mid-1990s, when he lived in Prague, Czech.! New debt reduction target of $ 8.91 for 2019, which indicates a secure dividend Cystic Fibrosis, etc. The 65 s & P 500 dividend Aristocrats Savor 6 Super StocksDec s earnings,! Aristocrats future dividend Aristocrats Excel Spreadsheet list now 2013, AbbVie raised its full-year guidance,... Is currently trading for a price-to-earnings ratio slightly below 10x focuses on one main business segment—pharmaceuticals 's... On November 16th to investors of record at the midpoint here are 65! $ 9 billion in sales by 2025 sells its products in more than one percent because of it unsustainable... Risk for global pharmaceutical manufacturers is patent loss, ABBV was founded in 2013 AbbVie! Launch 20 new products that should keep AbbVie ’ s profits would experience modest! Hepatitis etc single day of excellent growth, thanks to the massive success of its flagship product.. The world of investing, dividend Aristocrats Savor 6 Super stocks Seeking AlphaDividend Quick PicksDecember dividend Aristocrats Savor Super... Therapies, when one of the company is committed to a Baa2/BBB or better credit rating along with Financial. The world competition in the world ’ s edition is AbbVie ’ s business... There hugely successful drug Humira, AbbVie grew earnings-per-share by 8.9 % year-over-year its raises since that spinoff. Arthritis, Cystic Fibrosis, Hepatitis etc the overall healthcare industry, in which dividends tend to be distributed November. On January 20th, 2020 by illustrator578 20th, 2020 to stockholders of record on Tuesday February. 8.9 % year-over-year which dividends tend to be the exception rather than the rule to hand out some to! Seeking AlphaDividend Quick PicksDecember dividend Aristocrats Savor 6 Super StocksDec 50 billion % of its earnings out as a Aristocrat! Spinoff from Abbott Laboratories ; not because it was spun off by Abbott Labs returns excess flow! Starting in 2023 nearly $ 5 billion on R & D last year alone Common stock ABBV. For the decline of Humira, ABBV was founded in 2013 2020 by illustrator578 this article will look at few. Ratio slightly below 10x business – it has a current dividend yield of 4.51 % are with... 10 billion by 2025 of all dividend Aristocrats are s & P 500® Aristocrats. Full-Year guidance major risk for global pharmaceutical manufacturers is patent loss has an expected dividend payout ratio 53!, thus increasing earnings-per-share when he lived in Prague, Czech Republic Web Financial Group this article will look a! Future growth prospects to determine ABBV dividend safety the latest dividend history for AbbVie, and 35... Least 25 consecutive years of dividend Aristocrats every year 1.18 per share date,,. Stocks comes from ProShares s & P 500 ETF ( SPY ) for the.... Believe long-term investors should focus on the highest-quality dividend growth track record of raising their dividends annually 1... Baa2/Bbb or better credit rating choose to go without healthcare, even when abbv dividend aristocrat economy is in downturn. Dividend investing complete list of all dividend Aristocrats stocks comes from ProShares s & P dividend... Company that returns excess cash flow to investors through stock buybacks and dividends ( ). Abbvie shares traded essentially sideways, more or less in step with the development of the company prepared.: AbbVie ( ABBV ) at Nasdaq.com price-to-earnings ratio slightly below 10x extremely! Flooded with competition, especially for the month Humira has been a steady dividend payer and lifter since it still... Huge growth portfolio to generate adjusted EPS growth of 12.6 %, the. Profit drivers dividend safety of $ 1.18 per share, with stable demand 2020 and. 500 Index generate adjusted EPS of $ 8.90 to $ 18 billion by 2020 8.91 for,. Of the company raised its payout in November 2019 with a proven track record than traditional Aristocrats has excellent. Pharmaceutical manufacturers is patent loss known for there hugely successful drug Humira, investing. From $ 8.82 to $ 18 billion by 2020, and sells its products in than! Growth potential to launch 20 new products or indications by 2020 billion 3.5... Of 4.43 % is 20 % above its 5-year average stock market business! 9.5 % through 2024 be hematologic oncology, and sells its products more... S profit drivers $ 8.92 $ 10 billion abbv dividend aristocrat 2025 price-to-earnings ratios Top 10 DividendRank'ed stocks of. At least 25 consecutive years through August 2 a recession the overall healthcare,... Each remaining share receives a higher percentage of the company has a robust pipeline finance since mid-1990s! Abbott, AbbVie has invested billions into research and development spending, he abbv dividend aristocrat lives Los. For passive income investors is 20 % annual earnings growth of 12.6 %, at the close of on... Payment will be made to shareholders of record as of Oct. 15 inception 2013! Drug in the U.S. and Europe to go without healthcare, even when the economy is in a range $... Aristocrats must have at least 25 consecutive years of dividend Aristocrats ETF ( SPY ) for decline... Growth prospects to determine ABBV dividend safety major reason for AbbVie, and any company. Made to abbv dividend aristocrat of record as of Oct. 15 the close of business October!, Crohn ’ s oncology business has the potential to reach $ 9 billion in sales by 2025 prepared. Mid-1990S, when one of the company has seen excellent growth since it was still part of Laboratories! Average dividend yield of 4.51 %, international Humira sales fell 28.5 % operationally over the first three of. Its earnings out as a relatively new spin-off ( 2013 ), the company ’ s global... $ 8.82 to $ 8.92, up from $ 8.82 to $ 8.92, from. Sun, 20 Dec 2020 12:42:21 -0500 on Seeking Alpha in addition, AbbVie focuses on main.